Rimegepant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Rimegepant
Rimegepant.svg
Clinical data
Synonyms BHV-3000, BMS-927711
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C28H28F2N6O3
Molar mass 534.57 g·mol−1
3D model (JSmol)

Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb,[1] it is currently under development by Biohaven Pharmaceuticals.[2]

Mechanism of action[edit]

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.[3]

References[edit]

  1. ^ "Drug Profile: Rimegepant". Adis Insight. 
  2. ^ "Rimegepant (BHV-3000) – for acute treatment of Migraine". Biohaven Pharmaceuticals. 
  3. ^ Diener, Hans-Christoph; Charles, Andrew; Goadsby, Peter J; Holle, Dagny (2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet Neurology. 14 (10): 1010. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.